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	 Low-grade	 serous	 carcinoma	 is	one	of	 the	five	major	histological	 types	of	ovarian	
carcinoma	associated	with	a	specific	biology.	We	reviewed	three	cases	from	our	institution	to	
demonstrate	the	variable	clinical	course	and	provide	a	brief	review	on	this	disease	entity.
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vasion	 by	 a	 quantitative	 threshold	 of	 an	 invasive	 area	 greater	
than	5	mm	in	extent.	The	classic	histological	pattern	of	invasion	










sulting	in	increased	efficacy	for	HGSC.19 A series of studies from 
MDACC	reported	that	LGSC	are	only	occasionally	responding	
to	 chemotherapy	 and	 highlight	 the	 importance	 of	 surgery.20-22 


































































weight	 loss	 and	menstrual	 irregularities.	Medical	 report	 from	
her	home	country	indicated	that	she	underwent	a	left	salpingo-
oophorectomy	and	omentectomy	and	postoperatively	 adjuvant	
chemotherapy	 for	 an	ovarian	 tumor.	On	 review	at	 our	 institu-
tion,	 she	 presented	with	 increasing	 abdominal	 girth,	 pain	 and	
shortness	of	breath.	A	Computerized	Topographical	 (CT)	scan	
revealed	a	 left	sided	pleural	effusion,	 free	 intraperitoneal	fluid	











liposomal	 doxorubicin	 40	mg/m2	Q28,	 unfortunately	 she	 died	
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nantly	of	APST	with	foci	of	 frank	 invasion	 just	exceeding	 the	
5	mm	threshold	representing	an	example	for	a	diagnosis	of	an	
LGSC	at	the	lower	end	of	the	spectrum.	All	recurrences	of	this	
Figure 1:  (A) Low-grade serous carcinoma with typical micropapillary low power architecture on the right and variant pattern on the left: 
so called micropapillary inside out pattern. In both pattern papillae are surrounded by non-epithelial lined cleft-like spaces. The nuclei are 
monomorphic lacking significant nuclear atypia (case A). 
(B) Low-grade serous carcinoma with typical micropapillary low power architecture and abundant psammoma bodies, which are often 
seen in low-grade serous carcinoma (so called psammocarcinoma being the extreme variant). The nuclei are monomorphic lacking 
significant nuclear atypia (case B). 
(C) Low-grade serous carcinoma with typical micropapillary low power architecture and monomorphic nuclei (case C)
(D) TP53 immunohistochemistry on specimen from case C displaying TP53 wild type pattern. This pattern is characterized by a heteroge-
neous expression of TP53 with variable intensity in 1-70% of tumor nuclei similar to normal fallopian tube (inset). This pattern is distinct 
from aberrant TP53 expression seen in high-grade serous carcinomas indicative of underlying TP53 mutation, which is characterized by 
either diffuse overexpression (>70% of nuclei displaying strong expression) or complete absence (lack of any expression with positive 
internal control from lymphocytes and fibroblasts, not shown). 
Case A Case B Case C
Age at diagnosis 48 55 33
Stage at diagnosis IIIC IIC IIIC




Time to from diagnosis 
to death (months) 227
Alive with  
disease 11
Time to from first  
recurrence to death 
(months)
114 Alive with  disease NA
WT1 Diffuse Diffuse Diffuse
TP53 Wild type Wild type Wild type
P16 Patchy Patchy Patchy
ER Diffuse Diffuse Diffuse
PR Negative Diffuse Negative
Table 1: Case characteristics.
                                         Gynecology and obstetrics research
Open Journal
http://dx.doi.org/10.17140/GOROJ-2-108




initial	 diagnosis	 is	 disputed,	 the	 survival	 from	 the	 first	 recur-
rence	was	still	greater	than	nine	years.	Another	diagnostic	issue	
is	illustrated	with	the	third	case	that	showed	solid	pattern	in	ad-
dition	 to	 the	 typical	micropapillary	 features	 (Figure	1C).	This	
solid	pattern	raised	the	differential	diagnosis	of	HGSC.	HGSC	








Chemotherapy	 can	 induce	 stable	 disease	 and	 achieve	 disease	
control,	but	responses	are	rare.	Similarly,	hormonal	therapy	may	
contribute	to	disease	control	but	response	rates	are	low	(9%)	and	












status of KRAS or BRAF	raising	the	question	whether	other	func-
tionally	redundant	aberrations	in	the	MAPK	pathway	were	pres-
ent	in	cases	wild	type	for	KRAS or BRAF	that	responded.	It	also	
suggests	that	some	LGSC	with	KRAS or BRAF mutation that did 
not	 respond	may	 have	 additional	 alterations	 inducing	 primary	






	 We	started	 to	manage	LGSC	differently	 from	HGSC.	
In	 the	 initial	 diagnostic	 setting,	we	 prefer	 upfront	 surgery	 for	
LGSC	while	neoadjuvant	chemotherapy	is	an	option	for	HGSC.	
Although	there	are	clinical	hints	for	LGSC	(younger	age,	lower	
CA125),31	we	 push	 for	 a	 tissue	 based	 diagnosis	 preferentially	
an	omental	core	biopsy.	These	biopsies	have	the	advantage	that	
immune-histochemical	 markers	 (panel	 of	 PAX8,	WT1,	 TP53,	
p16)	can	be	more	reliably	compared	to	cell	blocks	obtained	from	
ascites.6	Because	LGSC	has	only	recently	been	recognized,	we	
will	 see	 recurrences	 of	 what	 was	 diagnosed	 well-differentiat-
ed	serous	carcinoma	 in	 the	past	 for	 the	upcoming	years.	Alert	
should	be	raised	if	the	patients	are	younger,	presents	with	mul-
tiple	or	 late	 recurrences	 that	do	not	 respond	 to	 chemotherapy.	
However,	this	can	overlap	with	patients	with	HGSC	carrying	a	




	 In	 summary,	 LGSC	 is	 a	 separate	 disease	 entity	 with	
variable	clinical	outcome.	The	variable	outcome	depends	on	the	
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